Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Icu Medical (ICUI) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Icu Medical (ICUI) over the last 11 years, with Q3 2025 value amounting to $3.0 million.

  • Icu Medical's Other Operating Expenses changed N/A to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.4 million, marking a year-over-year increase of 127380.95%. This contributed to the annual value of -$5.4 million for FY2024, which is 6676.92% up from last year.
  • Latest data reveals that Icu Medical reported Other Operating Expenses of $3.0 million as of Q3 2025.
  • Icu Medical's Other Operating Expenses' 5-year high stood at $41.8 million during Q2 2025, with a 5-year trough of -$27.2 million in Q2 2022.
  • For the 5-year period, Icu Medical's Other Operating Expenses averaged around -$377666.7, with its median value being -$769000.0 (2022).
  • As far as peak fluctuations go, Icu Medical's Other Operating Expenses tumbled by 37625.3% in 2023, and later surged by 14214.29% in 2024.
  • Quarter analysis of 5 years shows Icu Medical's Other Operating Expenses stood at $127000.0 in 2021, then plummeted by 759.84% to -$838000.0 in 2022, then tumbled by 376.25% to -$4.0 million in 2023, then soared by 64.72% to -$1.4 million in 2024, then surged by 310.87% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $41.8 million for Q2 2025, and -$1.4 million during Q4 2024.